期刊文献+

阿托伐他汀对心脏成纤维细胞MMP-9/TIMP-1表达的影响 被引量:2

Effects of atorvastatin on the expression of MMP-9/TIMP-1 in cardiac fibroblasts
下载PDF
导出
摘要 目的:观察阿托伐他汀(atorvastatin)对心脏成纤维细胞基质金属蛋白酶-9/组织型基质金属蛋白酶抑制因子-1(MMP-9/TIMP-1)表达的影响。方法:体外培养乳鼠心脏成纤维细胞(CF),做细胞形态观察和心脏成纤维细胞标志性波形蛋白免疫荧光组化检测,明胶酶谱法测定MMP-9的活性,RT-PCR检测MMP-9和TIMP-1mRNA的表达。结果:AngⅡ增加MMP-9的活性及mRNA的表达(P<0.05),同时TIMP-1的mRNA表达减少(P<0.05),阿托伐他汀在某种程度上可逆转上述变化(P<0.05)。结论:Aorvastatin通过对MMP-9/TIMP-1表达的影响作为预防和治疗房颤的重要机制之一。 Objective:To study the effects of atorvastatin on the expression of MMP-9/TIMP-1 in cardiac fibroblasts(CF).Methods: Cardiac fibroblasts of neonatal rats were cultured in vitro,cell morphology was observed.As one of the characters of CFS,protein vimentin was detected with immunofluorescence histochemistry.The activity of MMP-9 was measured by gelatinase zymograph,and mRNAs of MMP-9 and TIMP-1 were detected by RT-PCR.Results:The activity and the mRNA expression of MMP-9 were increased by AngⅡ(P0.05),while the expression of TIMP-1 was decreased.Atorvastatin can reverse the above changes to some extent.Conclusion:Through modulating the expression of MMP-9/TIMP-1,atorvastatin may play an important role in the prevention and treatment of atrial fibrillation.
出处 《西北国防医学杂志》 CAS 2011年第2期112-114,共3页 Medical Journal of National Defending Forces in Northwest China
关键词 房颤 阿托伐他汀 心脏成纤维细胞 基质金属蛋白酶-9 组织型基质金属蛋白酶抑制因子-1 Atrial fibrillation Cardiac fibroblasts Atorvastatin Cardiac fibroblasts Matrix metalloproeinases-9 Tissue inhibitor of matrix metalloproteinase-1
  • 相关文献

参考文献7

  • 1Naji F,Suran D,Kanic V,et al.Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after successful cardioversion[J].Int Heart J,2009,50(2):153-160.
  • 2Zhao J,Li J,Li W,et al.Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing[J].Br J Pharmacol,2010,159(8):1584-1594.
  • 3Anné W,Willems R,Roskams T,et al.Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation[J].Cardiovasc Res,2005,67(4):655-666.
  • 4Malik J,Stulc T,Ceska R,et al.Matrix metalloproteinases in isolated hypercholesterolemia[J].Int Angiol,2005,24(3):300-303.
  • 5Chen CL,Huang SK,Lin JL,et al.Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation[J].J Mol Cell Cardiol,2008,45(6):742-753.
  • 6朱慧,张薇,郭辰虹,张供,张维东,钟明,杨贵荣,葛志明,张运.心房肌基质金属蛋白酶-9和组织金属蛋白酶抑制因子-1表达改变对房颤心房重构机制的研究[J].中华医学杂志,2005,85(1):45-48. 被引量:30
  • 7Nakano Y,Niida S,Dote K,et al.Matrix metalloprotrinase-9 contributes to human atrial remodeling during atrial fibrillation[J].J Am Coll Cardiol,2004,43(5):818-825.

二级参考文献9

  • 1Spinale FG, Coker ML, Bond BR, et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart : a potential therapeutic target. Cardilvasc Res, 2000, 46:225-238.
  • 2Saharinen J, Hyytiainen M, Taipale J, et al. Latent transforming growth factor-beta binding proteins ( LTBPs ) structural extracellular nmtrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev, 1999, 10 : 99-117.
  • 3Peterson JT, Li H, Dillon L, et al. Evolution of matrix metalloproteinase and tissue inhibitor expression during heart failure progression int infracted rat. Cardiovasc Res, 2000, 46:307-315.
  • 4Nagahiro N, Kazuhiro Y, Yasushi S, et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res, 2003, 57:766-774.
  • 5Ducharme A , Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest, 2000, 106:55-62.
  • 6Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metallproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure . Nat Med, 1999, 5:1135-1142.
  • 7Borg TK, Burgess ML. Holding it all together: organization and function(s) of the extracellular matrix of the heart. Heart Failure,1993,8 : 230-238.
  • 8Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.Circulation, 1998, 98 : 1728-1734.
  • 9Roten L, Nemoto S, Simsic J, et al. Effects of gene diletion of the tissue inhibitor of the matrix metalloproteinase-type 1 ( TIMP-1 ) on left ventricular geometry and function in mice. J Mol Cell Cardiol,2000, 32:109-120.

共引文献29

同被引文献40

  • 1张标,曾晓荣,杨艳,刘智飞,张瑜.心房颤动患者心房肌乙酰胆碱敏感钾通道基因表达变化的研究[J].泸州医学院学报,2004,27(3):192-195. 被引量:2
  • 2朱慧,张薇,郭辰虹,张供,张维东,钟明,杨贵荣,葛志明,张运.心房肌基质金属蛋白酶-9和组织金属蛋白酶抑制因子-1表达改变对房颤心房重构机制的研究[J].中华医学杂志,2005,85(1):45-48. 被引量:30
  • 3柯丹,许春萱,张建成,陈林,林亚洲,林立芳,胡锡衷.心房颤动患者心房组织中明胶酶的基因表达及活性变化[J].中华心血管病杂志,2005,33(2):137-142. 被引量:26
  • 4魏玲,刘斌,李丽娟,卢国良,侯宗柳,刘绍华,张亚林,张筱军.血管紧张素转换酶基因多态性与房颤心肌纤维化的相关性研究[J].西南国防医药,2007,17(6):704-706. 被引量:2
  • 5Schotten U, Verheule S, Kirchhof P, et al. Pathophysiological mech- anisms of atrial fibrillation : a translational appraisal [ J ]. Physiol Rev,2011,91 ( 1 ) :265 - 325.
  • 6Guo P, Wu C, Masaki T, et al. Subdose of fasudil suppresses myo- cardial fibrosis in aldosterone-salt-treated uninephrectomized rats [J]. Pharmazie,2011,66(9) :716 -719.
  • 7Lallier PL, Ducharme A, Keller PF, et al.' Angiotensin-converting en- zyme inhibition in hypertensive patients is associated with a reduc- tion in the occurrence of atrial fibrillation[ J]. J Am Coil Cardiol, 2004,44( 1 ) :159 - 164.
  • 8Dabrowski R, Borowiec A,Smolis-Bak E,et al. Effect combined spi- ronolactone - 13 blocker-enalapril treatment on occurrence of symp- tomatic atrial fibrillation episodes in patients with a history of parox- ysmal atrial fibrillation ( SPIR - AF study) [ J ]. Am J Cardiol, 2010,106(11) :1609 - 1614.
  • 9Bddt A,Scholl A, Garbade J. ACE - inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibril- lation [ J ]. Basic Res Cardio1,2006,101 ( 3 ) : 261 - 267.
  • 10Hanna IR,Heeke B,Bush H,et al. Lipid-lowering drug use is asso- ciated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction [ J ] Heart Rhythm, 2006,3 (8) :881.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部